Nov 30
09:00
Συντονιστές: Wischhusen J., Baxevanis C. N.
Insights into colorectal cancer immunity revealed by multidimensional spatial approaches
Interferon-induced lysosomal membrane permeabilization causes cDC1-deserts in tumors
10:10
10:40
12:15
Συντονιστές: Kotsakis A., Tsitsilonis O.
Tumor-derived exosomes in plasma of cancer patients induce stress and death in immune cells: danger from within
12:45
14:00
Συντονιστές: Pateras I., Martin O.
T-CELL RECEPTOR AND IMMUNE-RESPONSE GENE STUDIES IN P. Batsaki TUMOR MICROENVI-RONMENT AND PERIPHERAL BLOOD IN HEAD AND NECK CANCER PATIENTS
THE TCR Vβ REPERTOIRE COMPOSITION AS A PREDICTIVE BIOMARKER OF IMMUNOTHERAPY EFFICIENCY IN NON-SMALL CELL LUNG CANCER PATIENTS
KMT2C IS A TUMOR SUPPRESSOR IN BLADDER CANCER AND ITS LOSS LEADS TO FAVORABLE RESPONSE TO IMMUNOTHERAPY
REAL-WORLD DATA ON IMMUNOTHERAPY IN PATIENTS WITH SOFT TISSUE SARCOMA: A STUDY FROM THE HELLENIC GROUP OF SARCOMA AND RARE CANCERS
15:00
Συντονιστές: Baxevanis C. N., Umansky V.
The power of novel allogeneic CAR-T cell to treat malignant disorders
Tolerogenic onco-fetal proteins as emerging targets for novel therapies
16:10
16:30
Συντονιστές: Baxevanis C. N., Wischhusen J.
Peripheral blood biomarkers predicting clinical response to checkpoint blockade in melanoma
17:00
Dec 01
09:00
Συντονιστές: Karagiannis S., Inderberg E.
The biomarker utility of TCR repertoire for clinical responses to immunotherapy in NSCLC
Dissecting the tumor microenvironment in early breast cancer: clinical implications and novel insights
10:10
10:40
Συντονιστές: Seliger B., Frisan T.
Immunotherapy for cancer via reprogramming macrophages with IgE antibody
11:50
12:10
13:30
Συντονιστές: Karagiannis S., Chatzigeorgiou A.
CHARACTERIZATION OF A B-LIKE PHENOTYPE CELL FOUND IN COLON ADE-NOCARCINOMAS
The immune status of colorectal cancer patients reveals a deep impairment in relevant cellular effectors of the immune system
ASSESSING THE BEHAVIOUR OF THE GENOTOXIN-PRODUCING SALMONELLA ENTERICA IN PRO-CARCINOGENIC MOUSE MODELS
MICROENVIRONMENTAL CONDITIONS AND HLA-CLASS-I EXPRESSION OF BREAST CANCER
NEOADJUVANT CHEMORADIOTHERAPY OF RECTAL CANCER AND HLA-CLASS-I-RELATED MOLECULES EXPRESSION
15:00
16:10
16:40
Συντονιστές: Wischhusen J., Psyrri A.
Oncogenes and tumor suppressor genes as regulators for immune surveillance
17:10
Dec 02
09:00
10:35
11:00
Συντονιστές: Klinakis A., Kotsakis A.
State of the art of immunotherapy in the first line setting in NSCLC
The role of immunotherapy in gastric and gastroesophangeal cancer
12:10
13:30
Συντονιστές: Wischhusen J., Xagara A.
PROGNOSTIC SIGNIFICANCE OF SHP2 EXPRESSION IN NON-SMALL LUNG CANCER PATIENTS
CONCOMITANT CAUSES OF ANAEMIA IN A PATIENT WITH LUNG ADENOCARCINOMA UNDER anti-PD-1 IMMUNOTHERAPY
DISTINCT PROFILE OF PROLIFERATING CD8+/TCF1+ T CELLS AMONG DIFFERENT BREAST CANCER MOLECULAR SUBTYPES
Fc ENGINEERED MONOCLONAL ANTIBODIES FOR TRIPLE NEGATIVE BREAST CANCER THERAPY
EFFECT OF THE MEK INHIBITOR COBIMETINIB ON BRAF V600E MUTATED THYROID CARCINOMA
